NL7907791A - Werkwijze voor het zuiveren van interferon. - Google Patents
Werkwijze voor het zuiveren van interferon. Download PDFInfo
- Publication number
- NL7907791A NL7907791A NL7907791A NL7907791A NL7907791A NL 7907791 A NL7907791 A NL 7907791A NL 7907791 A NL7907791 A NL 7907791A NL 7907791 A NL7907791 A NL 7907791A NL 7907791 A NL7907791 A NL 7907791A
- Authority
- NL
- Netherlands
- Prior art keywords
- interferon
- solution
- glass beads
- beads
- elution
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 96
- 108010050904 Interferons Proteins 0.000 title claims description 96
- 229940079322 interferon Drugs 0.000 title claims description 95
- 238000000034 method Methods 0.000 title claims description 57
- 239000000243 solution Substances 0.000 claims description 79
- 239000011324 bead Substances 0.000 claims description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000011701 zinc Substances 0.000 claims description 26
- 229910052725 zinc Inorganic materials 0.000 claims description 26
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 24
- 239000013522 chelant Substances 0.000 claims description 23
- 235000002639 sodium chloride Nutrition 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 20
- 239000011521 glass Substances 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 18
- 238000005406 washing Methods 0.000 claims description 17
- 239000007853 buffer solution Substances 0.000 claims description 14
- 239000003463 adsorbent Substances 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 12
- 102000003996 Interferon-beta Human genes 0.000 claims description 11
- 108090000467 Interferon-beta Proteins 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000005373 porous glass Substances 0.000 claims description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 8
- 239000002953 phosphate buffered saline Substances 0.000 claims description 8
- 238000001179 sorption measurement Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 229920002684 Sepharose Polymers 0.000 claims description 4
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000000746 purification Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000007973 glycine-HCl buffer Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108010058237 plasma protein fraction Proteins 0.000 description 3
- 229940081857 plasma protein fraction Drugs 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- -1 i.e. Proteins 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011173 large scale experimental method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7907791A NL7907791A (nl) | 1979-10-23 | 1979-10-23 | Werkwijze voor het zuiveren van interferon. |
| GB8032954A GB2061285B (en) | 1979-10-23 | 1980-10-13 | Purification of interferon |
| US06/198,223 US4359389A (en) | 1979-10-23 | 1980-10-17 | Method for the purification of interferon |
| DE19803039566 DE3039566A1 (de) | 1979-10-23 | 1980-10-20 | Verfahren zur reinigung von interferon |
| CH7806/80A CH647158A5 (de) | 1979-10-23 | 1980-10-20 | Verfahren zur reinigung von interferon. |
| FR8022617A FR2467602A1 (fr) | 1979-10-23 | 1980-10-22 | Procede pour la purification d'interferon et interferon ainsi obtenu |
| CA000363070A CA1166959A (en) | 1979-10-23 | 1980-10-23 | Method for the purification of interferon |
| JP14926280A JPS5673028A (en) | 1979-10-23 | 1980-10-23 | Interferon purification |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7907791 | 1979-10-23 | ||
| NL7907791A NL7907791A (nl) | 1979-10-23 | 1979-10-23 | Werkwijze voor het zuiveren van interferon. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL7907791A true NL7907791A (nl) | 1981-04-27 |
Family
ID=19834063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7907791A NL7907791A (nl) | 1979-10-23 | 1979-10-23 | Werkwijze voor het zuiveren van interferon. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4359389A (OSRAM) |
| JP (1) | JPS5673028A (OSRAM) |
| CA (1) | CA1166959A (OSRAM) |
| CH (1) | CH647158A5 (OSRAM) |
| DE (1) | DE3039566A1 (OSRAM) |
| FR (1) | FR2467602A1 (OSRAM) |
| GB (1) | GB2061285B (OSRAM) |
| NL (1) | NL7907791A (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
| YU45104B (en) | 1980-04-03 | 1992-03-10 | Biogen Nv | Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host |
| JPS5810056A (ja) * | 1981-07-10 | 1983-01-20 | 株式会社クラレ | 血液浄化装置 |
| JPH0751511B2 (ja) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン２を含有してなる癌治療剤 |
| JPS58201794A (ja) * | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
| US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
| US4485017A (en) * | 1982-12-22 | 1984-11-27 | Cetus Corporation | Isolation of human interferon by immunosorbent and high performance liquid chromatography |
| IL67896A (en) * | 1983-02-13 | 1987-03-31 | Yeda Res & Dev | Two biologically active human gama interferon subtypes,purification thereof and pharmaceutical compositions containing them |
| CA1231306A (en) * | 1983-03-03 | 1988-01-12 | Erich Hochuli | Purification of interferon |
| US4723000A (en) * | 1983-07-05 | 1988-02-02 | Biospectrum, Inc. | Human interferon gamma and interleukin-2 |
| US4648975A (en) * | 1983-08-17 | 1987-03-10 | Pedro B. Macedo | Process of using improved silica-based chromatographic supports containing additives |
| US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US4846786A (en) * | 1987-04-30 | 1989-07-11 | Massachusetts Institute Of Technology | Bioreactor containing suspended, immobilized species |
| IT1222427B (it) * | 1987-07-31 | 1990-09-05 | Sclavo Spa | Procedimento per la purificazione di interferone |
| HU201100B (en) * | 1988-03-04 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Process for large-scale production of high purity human leukocyte alpha interferon with reduced endotoxin content and with improved therapeutic effect |
| EP0551535A1 (en) * | 1992-01-13 | 1993-07-21 | SCLAVO S.p.A. | Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| CZ20032526A3 (cs) | 2001-02-27 | 2003-12-17 | Maxygen Aps | Nové molekuly podobné interferonu beta |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| KR100524871B1 (ko) * | 2003-12-04 | 2005-10-31 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| DE102009032179A1 (de) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617401A1 (de) * | 1966-05-02 | 1972-02-17 | Centre Nat Rech Scient | Verfahren zur Herstellung von Interferon-Praeparaten |
| US4070284A (en) * | 1973-08-20 | 1978-01-24 | Hitachi, Ltd. | Liquid chromatography and apparatus for the same |
| NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
| DE2961658D1 (en) * | 1978-05-17 | 1982-02-18 | Thomae Gmbh Dr K | Process for preparing human interferon |
-
1979
- 1979-10-23 NL NL7907791A patent/NL7907791A/nl not_active Application Discontinuation
-
1980
- 1980-10-13 GB GB8032954A patent/GB2061285B/en not_active Expired
- 1980-10-17 US US06/198,223 patent/US4359389A/en not_active Expired - Lifetime
- 1980-10-20 DE DE19803039566 patent/DE3039566A1/de not_active Withdrawn
- 1980-10-20 CH CH7806/80A patent/CH647158A5/de not_active IP Right Cessation
- 1980-10-22 FR FR8022617A patent/FR2467602A1/fr active Granted
- 1980-10-23 JP JP14926280A patent/JPS5673028A/ja active Pending
- 1980-10-23 CA CA000363070A patent/CA1166959A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CH647158A5 (de) | 1985-01-15 |
| US4359389A (en) | 1982-11-16 |
| JPS5673028A (en) | 1981-06-17 |
| GB2061285B (en) | 1983-03-30 |
| CA1166959A (en) | 1984-05-08 |
| FR2467602A1 (fr) | 1981-04-30 |
| GB2061285A (en) | 1981-05-13 |
| DE3039566A1 (de) | 1981-05-21 |
| FR2467602B3 (OSRAM) | 1982-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL7907791A (nl) | Werkwijze voor het zuiveren van interferon. | |
| EP0101935B1 (de) | Verfahren zur Herstellung des C1-Inaktivators und seine Verwendung | |
| JP2644946B2 (ja) | ＩｇＧ− モノクロナール抗体の精製方法及びその使用方法 | |
| EP0011435B1 (en) | Method of purification of human fibroblast interferon | |
| CA1188244A (en) | Angiotropins of leukocytes and inflamed tissue and process for their preparation | |
| JP3438735B2 (ja) | 上清ｉｖ、特にｉｖ−４またはコーンフラクションｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法 | |
| JP4454311B2 (ja) | 生物学的に活性な顆粒球コロニー刺激因子の精製および／または単離方法 | |
| CN109929027B (zh) | 采用线性洗脱步骤的重组融合蛋白纯化方法 | |
| JPS63503352A (ja) | タンパク質の精製 | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| JP3360315B2 (ja) | ヒト血清アルブミンの高度精製方法 | |
| JPH07102147B2 (ja) | ヒト血清アルブミンの着色抑制方法 | |
| SU1591814A3 (ru) | Способ получения рекомбинантного ^-интерферона | |
| JPS6042336A (ja) | 免疫グロブリンの製造方法 | |
| JPS63108000A (ja) | 第８因子の精製方法 | |
| US6087123A (en) | Metal-containing ribonucleotide polypeptides | |
| JPH0479359B2 (OSRAM) | ||
| JPS6034916A (ja) | 第１ｘ因子および他のビタミンｋ依存性タンパク質の高純度精製 | |
| JPH08116985A (ja) | 遺伝子操作に由来するヒト血清アルブミンの精製方法 | |
| JP2521551B2 (ja) | 抗血友病因子の製造方法 | |
| WO1992014832A1 (fr) | Procedes pour la purification de fdlb humains | |
| EP0116571B1 (en) | Method for making gamma globulin-containing compositions | |
| JP2885212B2 (ja) | 遺伝子操作由来のヒト血清アルブミンより得られる高純度ヒト血清アルブミン含有組成物 | |
| JP2869417B2 (ja) | 遺伝子操作により得られるヒト血清アルブミン | |
| JPS641118B2 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |